Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 5/20 | 0.77 |
| ▸ | CDC7 | O00311 | 8/20 | 0.71 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.48 |
| ▸ | CDK2 | P24941 | 1/20 | 0.48 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4182065 | 0.92 | GCGR (0.86) | GCGRCDC7MAPK14CCNA2CDK2 | |
| SCHEMBL30741015 | 0.88 | GCGR (0.60) | GCGRCDC7HTTMAPK10SMN1; SMN2 | |
| SCHEMBL12095151 | 0.87 | GCGR (0.79) | GCGRCDC7MAPK14 | |
| SCHEMBL4763739 | 0.87 | GCGR (0.79) | GCGRCDC7MAPK14CCNA2CDK2 | |
| SCHEMBL4183471 | 0.87 | GCGR (0.78) | GCGRCDC7MAPK14CCNA2CDK2 | |
| SCHEMBL30741046 | 0.83 | GCGR (0.54) | GCGRCDC7HTTMAPK10SMN1; SMN2 | |
| SCHEMBL4192327 | 0.83 | CDC7 (1.00) | GCGRCDC7MAPK14CCNA2CDK2 | |
| Hydrochloric Acid SCHEMBL4190744 | 0.82 | CDC7 (0.97) | GCGRCDC7MAPK14CCNA2CDK2 | |
| SCHEMBL4181977 | 0.80 | GCGR (0.67) | GCGRCDC7MAPK14MAPTCCNA2 | |
| SCHEMBL4181373 | 0.80 | GCGR (0.67) | GCGRCDC7MAPK14HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9056854-B2 | Pyridyl- and pyrimidinyl-substituted pyrrole-, thiophene- and furane-derivatives as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2015-06-16 | — | — | US | disclosed |
| US-20150051237-A1 | PYRIDYL-AND PYRIMIDINYL-SUBSTITUTED PYRROLE-, THIOPHENE- AND FURANE-DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2015-02-19 | — | — | US | disclosed |
| US-8906934-B2 | Pyridyl-and pyrimidinyl-substituted pyrrole-, thiophene-and furane-derivatives as kinase inhibitors | Nerviano Medical Science S.R.L. (IT) | 2014-12-09 | — | — | US | disclosed |
| EP-2004623-B1 | PYRIDYL- AND PYRIMIDINYL-SUBSTITUTED PYRROLE-, THIOPHENE- AND FURANE-DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2013-10-09 | — | — | EP | disclosed |
| US-20120295906-A1 | PYRIDYL-AND PYRIMIDINYL-SUBSTITUTED PYRROLE-, THIOPHENE-AND FURANE-DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-11-22 | — | — | US | disclosed |
| US-8263604-B2 | Pyridyl- and pyrimidinyl-substituted pyrrole-, thiophene- and furane-derivatives as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-09-11 | — | — | US | disclosed |
| US-20090099221-A1 | PYRIDYL-AND PYRIMIDINYL-SUBSTITUTED PYRROLE-, THIOPHENE-AND FURANE-DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2009-04-16 | — | — | US | disclosed |
| EP-2004623-A1 | PYRIDYL- AND PYRIMIDINYL-SUBSTITUTED PYRROLE-, THIOPHENE- AND FURANE-DERIVATIVES AS KINASE INHIBITORS | Nerviano Medical Sciences S.r.l. (IT) | 2008-12-24 | — | — | EP | disclosed |
| WO-2007110344-A1 | PYRIDYL- AND PYRIMIDINYL-SUBSTITUTED PYRROLE-, THIOPHENE- AND FURANE-DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2007-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150051237-A1 | PYRIDYL-AND PYRIMIDINYL-SUBSTITUTED PYRROLE-, THIOPHENE- AND FURANE-DERIVATIVES AS KINASE INHIBITORS | CDK2, CDK1, CDK5 | GCGR 1152/4885CDC7 294/4885MAPK14 530/4885 |
| US-20090099221-A1 | PYRIDYL-AND PYRIMIDINYL-SUBSTITUTED PYRROLE-, THIOPHENE-AND FURANE-DERIVATIVES AS KINASE INHIBITORS | CDK2, CDK1, CDK5 | GCGR 1171/4885CDC7 294/4885MAPK14 530/4885 |
| US-20120295906-A1 | PYRIDYL-AND PYRIMIDINYL-SUBSTITUTED PYRROLE-, THIOPHENE-AND FURANE-DERIVATIVES AS KINASE INHIBITORS | CDK2, CDK1, CDK5 | GCGR 1152/4885CDC7 294/4885MAPK14 530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.